Vaxxas Revenue and Competitors
Estimated Revenue & Valuation
- Vaxxas's estimated annual revenue is currently $15M per year.
- Vaxxas's estimated revenue per employee is $115,385
- Vaxxas's total funding is $46.2M.
Employee Data
- Vaxxas has 130 Employees.
- Vaxxas grew their employee count by 17% last year.
Vaxxas's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Manufacturing and Operational Excellence | Reveal Email/Phone |
2 | Head Formulation & Analytical | Reveal Email/Phone |
3 | Head, Special Projects | Reveal Email/Phone |
4 | SVP Vaccine Alliances | Reveal Email/Phone |
5 | Head Early-Stage & Preclinical R&D | Reveal Email/Phone |
6 | SVP Quality | Reveal Email/Phone |
7 | Head Technical Performance Improvement | Reveal Email/Phone |
8 | Head Human Resources | Reveal Email/Phone |
9 | Head Clinical Operations & Supply | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
What Is Vaxxas?
Vaxxas is a company based out of Vaxxas Pty Ltd (ACN 152 205 242)c/- OneVentures Management Suite 304, Level 3, 1 Alfred Street, Sydney, NSW, Australia.
keywords:N/A
$46.2M
Total Funding
130
Number of Employees
$15M
Revenue (est)
17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Vaxxas News
CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Apr 20, 2022--. Vaxxas, a clinical-stage biotechnology company commercializing a...
Massachusetts-based Vaxxas has a patch delivery technology, HD-MAP, that uses an array of projections to get vaccines to immune cells below the surface of the...
Vaxxas has obtained an exclusive license to the SARS-CoV-2 spike subunit vaccine, HexaPro, from The University of Texas at Austin (UT...
Vaxxas, a Cambridge, Mass., USA, and Brisbane, Queensland, Australia-based biotechnology company commercializing a novel vaccination platform, secured A$25m [US$20m] series B equity funding. New and existing investors participated. This new round brought the total capital raised to A$40m [US$33 ...
Vaxxas plans to apply its patented patch technology to develop new vaccine forms for influenza, polio, bacterial infections and cancer. It already has collaborations underway with Merck to develop its Nanopatch for undisclosed vaccine candidates. The Series B round was led by Australian investm ...
Other Companies in Sydney
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $35.1M | 130 | 2% | N/A |
#2 | $19.5M | 130 | 34% | N/A |
#3 | $18.9M | 130 | 1% | N/A |
#4 | $27.3M | 130 | 38% | N/A |
#5 | $18.9M | 130 | N/A | N/A |